Fast Five Quiz: Are You Prepared to Confront Multiple Myeloma?

Emmanuel C Besa, MD; Dhaval Shah, MD


March 09, 2017

The 2015 National Comprehensive Cancer Network (NCCN) guidelines for multiple myeloma list the following combinations as preferred regimens (category 1) for primary induction therapy in patients who are not transplant candidates:

  • Lenalidomide/low-dose dexamethasone

  • Melphalan/prednisone/bortezomib (MPB)

  • Melphalan/prednisone/lenalidomide (MPL)

  • Melphalan/prednisone/thalidomide (MPT)

For more about the treatment of multiple myeloma, read here.

Related Resources


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.